JT
CGEM icon

Jupiter Topco’s Cullinan Oncology CGEM Stock Holding History

Jupiter Topco’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$337K Buy
+18,528
New +$275K ﹤0.01% 2265

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Jupiter Topco's CGEM Position: Q2 2026 in Review

Jupiter Topco opened a new position in Cullinan Oncology (CGEM) in Q2 2026: 18,528 shares worth $337K. The stake represents ﹤0.01% of the portfolio and ranks #2265 among its holdings.

167 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Jupiter Topco held 18,528 shares of Cullinan Oncology worth $337K as of Q2 2026.
  • Cullinan Oncology was a new Jupiter Topco position in Q2 2026.
  • Cullinan Oncology made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #2265 holding.
  • 167 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.